{"disease":{"id":"refractory-anemia-with-excess-blasts","name":"refractory anemia with excess blasts"},"drugs":{"marketed":[{"drug_id":"azacitidine","indication_name":"Refractory Anemia with Excess Blasts (RAEB)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vidaza","generic_name":"azacitidine","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"DNA (cytosine-5)-methyltransferase 1","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":61,"revenue":null,"mechanism":"Vidaza works by incorporating itself into DNA and interfering with the enzyme that adds methyl groups, which helps to restore normal gene function in cancer cells."},{"drug_id":"azacitidine","indication_name":"Refractory Anemia with Excess Blasts in Transformation (RAEB-T)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vidaza","generic_name":"azacitidine","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"DNA (cytosine-5)-methyltransferase 1","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":61,"revenue":null,"mechanism":"Vidaza works by incorporating itself into DNA and interfering with the enzyme that adds methyl groups, which helps to restore normal gene function in cancer cells."},{"drug_id":"chembl-chembl1489","indication_name":"Refractory Anemia with Excess Blasts (RAEB)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AZACITIDINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1489","indication_name":"Refractory Anemia with Excess Blasts in Transformation (RAEB-T)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AZACITIDINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":20,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02562443","title":"Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":372,"lead_sponsor_name":"Traws Pharma, Inc.","has_results":false},{"nct_id":"NCT00008177","title":"Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT02566304","title":"Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":true},{"nct_id":"NCT00589316","title":"Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":26,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT00540995","title":"Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":25,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT02553941","title":"Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Brian Jonas","has_results":false},{"nct_id":"NCT01834248","title":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}